Market outlook of the colorectal cancer therapeutics market in the APAC region
Colorectal cancer is a type of cancer that affects colon or rectum. The risk factors identified for this cancer include age, family history, unhealthy lifestyle, genetic disorders, and inflammatory bowel disease. Different types of therapy such as chemotherapy, surgical, biologic, and radiation therapy are being developed and administered to the colorectal patients to alleviate this disease.
Technavio’s analysts expect the colorectal cancer therapeutics market in the APAC region to grow at a moderate rate, posting a CAGR of more than 6% during the forecast period.
The presence of high unmet medical need is one of the major drivers propelling the growth of the market. Colorectal cancers cannot be cured completely by the currently available therapies and if it has not metastasized, surgery would be the only treatment option. As a result, a drug manufacturer has immense opportunities to exploit and seek a favorable position in the market by developing appropriate drugs and mitigate this issue.
End-user segmentation of the colorectal cancer therapeutics market in APAC
- Small molecules
- Biologics
The small molecules segment includes chemical entities characterized by low molecular weight and a less complex structure as compared to biologics. They are easy to manufacture through chemical synthesis, more stable than biologics, and mostly non-immunogenic.
Segmentation of the colorectal cancer therapeutics market in APAC by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
First-line chemotherapy therapy is the treatment regimen or regimens that are generally accepted by the medical establishment for primary treatment and stage of cancer. First-line therapy is also called as a standard therapy.
Competitive landscape and key vendors
The colorectal cancer therapeutics market in the APAC region is witnessing moderate growth because of a rise in the prevalence of colorectal cancer and unmet medical needs. Therefore, companies that manufacture and market drugs that can treat colorectal cancer effectively and cure, besides exhibiting a high safety and efficacy profile, are expected to gain a competitive edge over other companies in this market.
Key vendors in this market are -
- Amgen
- Bayer Healthcare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
Other prominent vendors included in this report are Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, AVEO Oncology, Bavarian Nordic, Biothera, Boehringer Ingelheim, Boston Biomedical, Celator Pharmaceuticals, Cancer Prevention Pharmaceuticals, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, EpicentRx, GlaxoSmithKline, Hutchison Medipharma, Immodulon Therapeutics, Immunomedics, MacroGenics, Merrimack Pharmaceuticals, Morphotek, Mologen, MolMed, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, PsiOxus Therapeutics, PledPharma, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, and Yakult Honsha.
Key questions answered in the report include
- What will the market size and the growth rate be in 2019?
- What are the key factors driving the colorectal cancer therapeutics market in APAC?
- What are the key market trends impacting the growth of the colorectal cancer therapeutics market in APAC?
- What are the challenges to market growth?
- Who are the key vendors in the colorectal cancer therapeutics market in APAC?
- What are the market opportunities and threats faced by the vendors in the colorectal cancer therapeutics market in APAC?
- What are the key outcomes of the five forces analysis of the colorectal cancer therapeutics market in APAC?
Technavio also offers customization on reports based on specific client requirement.
Related reports
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Vectibix
PART 03: Product profiles
- Stivarga
- Erbitux
- Xeloda
- Avastin
- Zaltrap
PART 04: Market research methodology
- Research methodology
- Economic indicators
PART 05: Introduction
PART 06: Disease overview
- Understanding the disease
- High risk factors
- Signs and symptoms
- Pathophysiology
- Diagnosis
- Staging
- Biomarker testing
- Epidemiology
- Treatment
PART 07: Pipeline portfolio
- Information on pipeline candidates
PART 08: Market landscape
- Market overview
- Market size and forecast
- Colorectal cancer therapeutics market in Japan
- Colorectal cancer therapeutics market in China
- Five forces analysis
PART 09: Market segmentation by based on the type of molecules
- Small molecules
- Biologics
PART 10: Market segmentation by route of administration
PART 11: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
- Amgen
PART 18: Key vendor analysis
- Bayer HealthCare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
PART 19: Appendix
PART 20: Explore Technavio